CureVac Shareholders Face Critical Acquisition Deadline
Veröffentlicht: 05.11.2025 um 04:19 Uhr, Redaktion boerse-global.de
The biotechnology sector is watching closely as BioNTech’s proposed acquisition of CureVac enters its decisive phase. With a November 25 shareholder meeting approaching, investors must determine whether to accept the takeover bid that could reshape the mRNA therapeutics landscape.
BioNTech has established clear parameters for its acquisition proposal, offering approximately $5.46 per CureVac share through American Depositary Shares (ADSs) of its own stock. This values the potential transaction at around $1.25 billion. However, the deal contains a critical contingency: it requires acceptance from at least 80% of CureVac shareholders to proceed. BioNTech has indicated it would only consider lowering this threshold to 75% under exceptional circumstances.
The exchange mechanism introduces additional complexity. Read more...
Disclaimer zu unseren Artikeln: Keine Anlageberatung, keine Kauf oder Verkaufsempfehlung. Angaben zu Kursen, Unternehmen und Märkten ohne Gewähr; Änderungen jederzeit möglich. Börsengeschäfte können zu hohen Verlusten führen. Unsere Beiträge werden ganz oder teilweise automatisiert mit Unterstützung von AI erstellt und geprüft.
